Showing results (281-290 of 481) with videos related to
Sort By:
Pageof 49
Blood|October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemiaSarah K Tasian, David T Teachey, Yong Li, et al.Cancer Discovery|June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology GroupElliot Stieglitz, Alex G Lee, Steven P Angus, et al.Leukemia & Lymphoma|November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trialsMichael J Burke, Meenakshi Devidas, Kelly Maloney, et al.Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.Pediatric Blood & Cancer|June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.Blood|June 2, 2005
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative diseaseChristian P Kratz, Charlotte M Niemeyer, Robert P Castleberry, et al.SLAS Discovery : Advancing Life Sciences R & D|May 11, 2018
High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALLDominique R Perez, Christian K Nickl, Anna Waller, et al.International Journal of Cancer|August 4, 2015
Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331Hannah-Rose Mitchell, Xiaomin Lu, Regina M Myers, et al.Blood|December 30, 2017
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALLBrent Wood, David Wu, Beryl Crossley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2017
Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology GroupNaomi Winick, Meenakshi Devidas, Si Chen, et al.Pageof 49